EXAS · As filed with the SEC
Exact Sciences income statement, by quarter
The statement as Exact Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|
| Net loss | (85,955)† | (19,594) | (1,185) | (101,215) | (864,585) |
| Net loss before tax | (85,083)† | (17,757) | (57) | (100,991) | (875,966)† |
| Loss from operations | (82,595)† | (25,545) | (2,148) | (96,010) | (876,351) |
| Gross profit | 615,826† | 583,929 | 562,453 | 500,547 | 492,593 |
| Revenue | — | 850,739 | 811,085 | 706,785 | — |
| Revenue | — | — | — | — | 713,424 |
| Cost of sales | 262,555† | 266,810 | 248,632 | 206,238 | 220,831 |
| Total operating expenses | 698,421† | 609,474 | 564,601 | 596,557 | 1,371,512† |
| Research and development | 191,495† | 117,290 | 108,901 | 105,310 | 97,709 |
| Sales and marketing | 288,527† | 250,228 | 247,118 | 264,310 | 244,529 |
| General and administrative | 217,993† | 241,413 | 208,582 | 220,686 | 191,110 |
| Impairment of long-lived and indefinite-lived assets | 406† | 543 | 0 | 6,251 | 838,164 |
| Other operating income | 0† | 0 | 0 | 0 | 2,568 |
| Total other income (expense) | (2,488)† | 7,788 | 2,091 | (4,981) | 385 |
| Investment income, net | 7,271† | 17,577 | 11,926 | 4,997 | 9,962† |
| Interest Expense, Nonoperating | (9,759)† | (9,789) | (9,835) | (9,978) | (9,577)† |
| Income Tax Expense (Benefit) | (872)† | (1,837) | (1,128) | (224) | 11,381 |
| Increase (decrease) in net loss per share (in usd per share) | — | (0.10) | (0.01) | (0.54) | (4.67) |
| Increase (decrease) in net loss per share (in usd per share) | — | (0.10) | (0.01) | (0.54) | (4.67) |
| Weighted average number of shares outstanding, basic (in shares) | — | 189,262 | 188,902 | 186,813 | 185,312 |
| Weighted average number of shares outstanding, diluted (in shares) | — | 189,262 | 188,902 | 186,813 | 185,312 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.